TUCSON, Ariz. — Picard Medical, Inc. (NYSE American: PMI), parent company of SynCardia Systems LLC and maker of the world’s first U.S. and Canadian commercially approved total artificial heart, announced it will exhibit at the 2025 annual meeting of the American Heart Association (AHA), taking place November 7–10 in New Orleans, Louisiana.
At the event, Picard will highlight its SynCardia Total Artificial Heart (STAH), the most widely used and extensively studied artificial heart worldwide. The company will showcase the technology and engage with attendees at booth #3408.
“We are excited to attend the annual meeting of the American Heart Association to share the latest developments related to our innovative and life-saving artificial heart, the Syncardia Total Artificial Heart, or STAH,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical, Inc. “We look forward to having discussions with physicians and attendees at AHA about patient eligibility, the latest clinical data and helpful resources, and sharing insights from patients who have had real-world experiences with the STAH.”
The AHA’s annual meeting (#AHA25) brings together the full spectrum of cardiovascular science—from foundational and translational research to clinical trials and real-world applications. Each year, thousands of professionals collaborate to advance cardiovascular health globally.
The American Heart Association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. Its mission unites more than 35 million volunteers and supporters, along with more than 3,300 employees, in the pursuit of improving cardiovascular health and saving lives.
